P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis

P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis
复制标题

P53缺乏影响胆固醇酯化加剧肝癌发生

DOI:
10.1002/hep.32518
复制
发表时间:
2022-04
期刊:
影响因子:
13.5
通讯作者:
Youjun Li
Youjun Li
中科院分区:
医学1区
文献类型:
--
作者:
Yahui Zhu;Li Gu;Xi Lin;Xinyi Zhou;Bingjun Lu;Cheng Liu;Yajun Li;Edward V. Prochownik;Michael Karin;Fubing Wang;Youjun Li

文献摘要

参考文献

相似文献

背景和目标:胆固醇酯(CE)的生物合成和稳态在许多癌症中起着关键作用,包括HCC,但它们对HCC疾病发展的确切机制需要进一步研究。方法和结果:在这里,我们报告了一个建议的作用,肿瘤抑制P53在其抑制泛素特异性肽酶19(USP 19)和甾醇O-酰基转移酶(SOAT)1,维持CE稳态。USP 19通过去泛素化和稳定SOAT 1增强胆固醇酯化并促进肝癌发生(HCG)。SOAT 1或USP 19的缺失显著减弱了用正常食物饮食或高胆固醇、高脂肪饮食(HCHFD)喂养的P53缺陷小鼠的胆固醇酯化和HCG。与从头胆固醇合成抑制剂相比,SOAT 1抑制剂avasimibe对HCHFD维持的P53缺陷小鼠中HCC进展具有更大的抑制作用。与我们在小鼠模型中的发现一致,P53-USP 19-SOAT 1信号轴在人类HCC中也失调。结论:总的来说,我们的研究结果表明,SOAT 1参与HCG通过增加胆固醇酯化,从而表明SOAT 1是一个潜在的生物标志物和治疗靶点在P53缺陷型肝癌。
Background and aims: Cholesterol ester (CE) biosynthesis and homeostasis play critical roles in many cancers, including HCC, but their exact mechanistic contributions to HCC disease development require further study...Approach and results: Here, we report on a proposed role of tumor suppressor P53 in its repressing ubiquitin-specific peptidase 19 (USP19) and sterol O-acyltransferase (SOAT) 1, which maintains CE homeostasis. USP19 enhances cholesterol esterification and contributes to hepatocarcinogenesis (HCG) by deubiquitinating and stabilizing SOAT1. Loss of either SOAT1 or USP19 dramatically attenuates cholesterol esterification and HCG in P53-deficient mice fed with either a normal chow diet or a high-cholesterol, high-fat diet (HCHFD). SOAT1 inhibitor avasimibe has more inhibitory effect on HCC progression in HCHFD-maintained P53-deficient mice when compared to the inhibitors of de novo cholesterol synthesis. Consistent with our findings in the mouse model, the P53-USP19-SOAT1 signaling axis is also dysregulated in human HCCs...Conclusions: Collectively, our findings demonstrate that SOAT1 participates in HCG by increasing cholesterol esterification, thus indicating that SOAT1 is a potential biomarker and therapeutic target in P53-deficient HCC.
DOI: 10.1016/j.cmet.2014.01.019
发表时间: 2014-03-04
期刊: Cell metabolism
影响因子: 29
作者:
Yue S;Li J;Lee SY;Lee HJ;Shao T;Song B;Cheng L;Masterson TA;Liu X;Ratliff TL;Cheng JX
通讯作者: Cheng JX
DOI: 10.3410/f.726427886.793521202
发表时间: 2016
期刊: --
影响因子: --
作者:
T. Sallam;Marius C. Jones;T. Gilliland;Li Zhang;Xiaohui Wu;Ascia;Eskin;J. Sandhu;D. Casero-D.-Cas
通讯作者: T. Sallam;Marius C. Jones;T. Gilliland;Li Zhang;Xiaohui Wu;Ascia;Eskin;J. Sandhu;D. Casero-D.-Cas
DOI: 10.1158/0008-5472.can-18-0340
发表时间: 2018-10-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Gu, Li;Zhu, Yahui;Li, Youjun
通讯作者: Li, Youjun
DOI: 10.1016/j.cell.2018.11.011
发表时间: 2019-01-24
期刊: CELL
影响因子: 64.5
作者:
Moon, Sung-Hwan;Huang, Chun-Hao;Prives, Carol
通讯作者: Prives, Carol
DOI: 10.1210/en.2018-00290
发表时间: 2018-08-01
期刊: ENDOCRINOLOGY
影响因子: 4.8
作者:
Coyne, Erin S.;Bedard, Nathalie;Wing, Simon S.
通讯作者: Wing, Simon S.